Acurx Pharmaceuticals Announces Paradigm-Shifting Clinical Trial for Ibezapolstat in Recurrent C. difficile Infection (rCDI)

Key Highlights for Investors

• Initiation of a Groundbreaking Clinical Trial: Acurx Pharmaceuticals (Nasdaq: ACXP) is launching a new clinical trial with ibezapolstat targeting patients with multiply-recurrent C. difficile infection (rCDI). This trial could shift current treatment paradigms from a two-drug regimen to a single-agent solution.
• Exceptional Phase 2 Results: In previous Phase 2 studies, ibezapolstat demonstrated a 96% clinical cure rate in patients with acute CDI, and notably, none of the successfully treated patients experienced recurrence within one month. Extended follow-up data revealed that all monitored patients remained recurrence-free for three months.
• Favorable Microbiome Impact: Emerging data show that ibezapolstat spares beneficial gut microbiota and improves the ratio of secondary-to-primary bile acids, both of which are associated with reduced CDI recurrence.
• Regulatory Momentum: Ibezapolstat has received FDA Fast Track and QIDP designations, as well as SME status from the EMA, all supporting expedited development and review.
• Potential for Expedited Approval: The company will pursue FDA approval for both treatment and prevention of rCDI under the Limited Population Pathway for Antibacterial and Antifungal Drugs, leveraging recent FDA guidance that may allow for a one-pivotal-trial approval structure.
• Significant Market and Public Health Impact: rCDI accounts for a \$2.8 billion annual burden in the U.S. alone, out of an estimated \$5 billion total related to CDI. An effective one-drug solution could capture significant market share and address a major unmet need.

Detailed Overview

Clinical Trial and Program Advancement

Acurx is initiating an open-label clinical trial that will enroll up to 20 patients with at least two recurrences of CDI after standard antibiotic treatment in the past 12 months. This pilot trial is expected to start patient enrollment in Q4 this year. Results will inform the design of a planned active-controlled Phase 3 registration trial for rCDI, which, if successful, could lead to FDA approval under the Limited Population Pathway.

The company’s broader CDI program is also Phase 3-ready, pending funding. The trial will be international in scope, with the EMA providing positive feedback and supporting the proposed Phase 3 design. The trial will randomize approximately 450 subjects in a 1:1 ratio to ibezapolstat or vancomycin and will evaluate both clinical cure and recurrence, with potential for a superiority analysis if non-inferiority is established.

Clinical Data and Microbiome Insights

In a combined Phase 2a/2b clinical trial, ibezapolstat achieved a 96% clinical cure rate (25 of 26 patients) and a 100% sustained cure rate at one month. In comparison, vancomycin-treated patients had an 86% sustained cure rate. Notably, all ibezapolstat-cured patients monitored up to three months remained recurrence-free.

Microbiome analysis revealed that ibezapolstat treatment led to overgrowth of healthy gut bacteria (Actinobacteria and Firmicute phyla) and a favorable shift in bile acid metabolism, both of which are correlated with reduced CDI recurrence. These effects distinguish ibezapolstat from current standards of care, which can disrupt the microbiome and increase recurrence risk.

Recent unpublished data from Dr. Kevin Garey’s laboratory (University of Houston) reinforced the view that beneficial bacteria persist after ibezapolstat therapy, and these findings will be disclosed at the Anaerobe Society of the Americas conference in July 2026.

Regulatory and Market Outlook

Ibezapolstat’s regulatory status is strong: it is designated a Qualified Infectious Disease Product (QIDP) and has Fast Track status from the FDA, plus SME status from the EMA. The company is poised to move quickly through the remaining clinical and regulatory steps, especially in light of recent FDA commentary suggesting a new default of a single pivotal trial for registration.

According to Acurx, successful development of ibezapolstat could be a “game changer” for the estimated 500,000 CDI cases and 30,000 deaths annually in the U.S., with a particularly large impact on the \$2.8 billion rCDI segment.

The company is holding an earnings call on March 13, 2026 to discuss these developments in detail, and the R&D team will be available for Q&A.

Strategic Implications for Shareholders

• Potential for Market Leadership: If ibezapolstat is approved for both treatment and prevention of rCDI, it could become the first single-agent solution in this space, potentially capturing significant market share from incumbents vancomycin and fidaxomicin.
• Regulatory Tailwinds: Fast Track and QIDP designations, plus the possibility of one-trial approval, could accelerate time-to-market and reduce development costs.
• Phase 3-Ready Asset: The company is ready to commence international Phase 3 trials, subject to funding, and has achieved positive regulatory guidance from both FDA and EMA.
• Significant Unmet Need: High recurrence rates after current standard treatments (up to 40% in high-risk patients) underscore the urgent need for a more effective solution like ibezapolstat.

Conclusion

This announcement contains several price-sensitive catalysts: the launch of a new clinical trial that could redefine CDI and rCDI treatment; robust Phase 2 data that de-risk the Phase 3 program; regulatory fast-tracking and the possibility of a one-trial approval pathway; and a large, underserved market. Investors should closely monitor trial enrollment, upcoming conference disclosures, and regulatory updates.

Disclaimer: This article contains forward-looking statements as defined under U.S. securities law. Actual results may differ materially due to risks and uncertainties discussed in Acurx Pharmaceuticals’ SEC filings. This is not investment advice. Please consult your financial advisor before making investment decisions.

View Acurx Pharmaceuticals, Inc. Historical chart here